Partnership is Awakn’s first with a dedicated addiction treatment clinic, Ken Starr MD Wellness Group TORONTO, CANADA, Feb 28, 2023 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a…

Awakn Will License its Protocols for Treating Addiction and Mental Health to a Healthcare Consortium to Help Accelerate Their Development of a Chain of Clinics in Portugal TORONTO, CANADA, Feb…

Awakn Clinics Trondheim is its second clinic in Norway TORONTO, CANADA, Feb 14, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to…

TORONTO, CANADA, February 9, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol…

Designation Aims to Accelerate Time to Market TORONTO, CANADA, February 7, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction…

Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II TORONTO, CANADA, January 24, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”),…

And continued successful execution of R&D and Commercialization strategies TORONTO, CANADA, December 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company, researching, developing,…

Phase III trial confirmed to cost CA$3.75 million, with UK Government agencies funding 66% of this cost TORONTO, CANADA, 13 Nov, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF,…

Trondheim in central Norway will be the location of Awakn’s 4th clinic TORONTO, CANADA, Dec 1, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company…

Awakn’s Nordic expansion begins with new Awakn Clinics Oslo TORONTO, CANADA, Nov 23, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and…

TORONTO, CANADA, 17 Nov, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

Awakn will Partner with Nushama, One of New York’s Leading Ketamine-assisted Therapy Centers TORONTO, CANADA, Nov 9, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology…

Awakn will receive approx. CAD$775K to grow its Nordic clinics business TORONTO, CANADA, Oct 25, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a revenue-generating biotechnology company researching,…

Awakn delivered revenue growth of 34% in Q2 Awakn also announces closing of first tranche of private placement financing TORONTO, CANADA, Sept 15, 2022 – Awakn Life Sciences Corp. (NEO:…

TORONTO, CANADA, Sept, 12 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine TORONTO, CANADA, August 25, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…

Licensing Partnership with Wellbeings® marks entry into Canadian addiction treatment and relapse prevention market TORONTO, CANADA, August 18, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…

Awakn enters the U.S. addiction treatment and relapse prevention market TORONTO, CANADA, August 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing,…

Phase III Trial to Cost ~CA$3.75 million with Awakn’s contribution expected to be ~CA$1.25 million Marks First Psychedelic Phase III Trial Ever to Receive Government Funding TORONTO, CANADA, 20 July,…

TORONTO, CANADA, July 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III TORONTO, CANADA, July 05, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE:…

TORONTO, CANADA, June 20, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term…

Awakn delivered revenue growth of 24% in the quarter TORONTO, CANADA, June 14, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…

Seasoned Leader Brings Deep Knowledge of US Biotech Market to Awakn TORONTO, CANADA, June 7, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…

Study Initiated Following Recent Successful Pilot Study and Patent Filing TORONTO, CANADA, June 2, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…

Successful Behavioral Addiction Study Supplied Data for Patent TORONTO, CANADA, May 26, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and commercializing…

TORONTO, CANADA, May 24, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus…

Promising Results Merit Larger Study Which Awakn is Initiating TORONTO, CANADA, May 19, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and…

Dr. Dhandayudham Brings Significant Frontline Addiction and Mental Health Medical Leadership Experience to Awakn TORONTO, CANADA, May 17, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a…

TORONTO, CANADA, April 28, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction,todayis reporting…

TORONTO, CANADA, April 13, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, today is providing shareholders with…

Two Chemical Series Identified To Facilitate Lead Optimisation Activities TORONTO, CANADA, April 6, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering…

Toronto, Canada–(Newsfile Corp. – April 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat…

Toronto, Ontario–(Newsfile Corp. – March 22, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a biotechnology company, researching, developing and delivering psychedelic…

London Clinic Will Begin Delivering Ketamine-Assisted Therapy for Addiction & Mental Health. Third Location Adds to Two Existing Operatons in Bristol and Oslo. Toronto, Ontario–(Newsfile Corp. – March 17, 2022)…

Brings Over 20 Years of Commercial Biotech Experience to Lead Awakn’s Therapeutics Commercialization Activities in the U.S. TORONTO, CANADA, MARCH 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:…

TORONTO, CANADA, March 09, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that…

Entactogen NCE series enhances the potential to treat a broad range of addictions TORONTO, CANADA, FEBRUARY 17, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…

Professor Morgan, Awakn’s Head of Ketamine-Assisted Therapy for Addiction, named one of the 16 most influential women shaping the future of psychedelics by Insider TORONTO, CANADA, 15 February 2022 – Awakn…

Dr. Sessa Will Discuss the Promise of Psychedelic Medicine in Treating Addiction Toronto, Ontario–(Newsfile Corp. – February 10, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954)…

Novel Entactogen NCE series enhances the potential for improved treatment of addiction TORONTO, CANADA, 26 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching,…

Agreement to explore a partnership for MDMA-Assisted Therapy for treatment of Alcohol Use Disorder in Europe TORONTO, CANADA, 19 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF)…

Primary and secondary endpoints achieved, including 86% abstinence over 6 months post treatment and no serious adverse events. TORONTO, CANADA, 11 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…

Groundbreaking Psychedelic study will investigate Binge Eating Disorder, Compulsive Sexual Behavior, and Internet Gaming Disorder TORONTO, CANADA, 05 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:954) (Awakn), a biotechnology company developing…

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding shares. TORONTO, CANADA, 04 January 2022 – Awakn Life Sciences Corp….

TORONTO, CANADA, 15 DECEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN)  (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat…

TORONTO, CANADA, December 14, 2021 – Awakn Life Sciences Corp. (NEO: AWKN)  (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the appointment…

Kate Butler To Be Appointed CFO, Jonathan Held, Current CFO, To Be Appointed Chief Business Officer. TORONTO, CANADA, 30 November 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’…

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III Toronto, Ontario (November 16, 2021) – Awakn Life Sciences Corp….

Worlds’s First Controlled Study To Investigate Ketamine-Assisted Psychotherapy TORONTO, CANADA, November 4, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines…

Toronto, Ontario–(Newsfile Corp. – November 2, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies)…

This Further Defines Development Pathways For Next Generation Of Psychedelic Medicines To Treat Addiction. TORONTO, CANADA, October 28, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology…

TORONTO, CANADA, 22 OCTOBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Chief…

The clinic will begin delivering ketamine-assisted psychotherapy treatments in October. TORONTO, CANADA, 20 October 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…

Transaction concludes with the launch of “Awakn Clinics Oslo AS” as part of Awakn Life Sciences Nordic Expansion  TORONTO, October 05, 2021 – Awakn Life Sciences Corp. (“Awakn” or the “Company”),…

This was the world’s first published study assessing MDMA-assisted psychotherapy as a treatment for addiction TORONTO, September 23, 2021 – Awakn Life Sciences Corp. (Awakn), (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) a…

Launches Nordics Regional Expansion Dr. Lowan Stewart, One of Europe’s Preeminent Ketamine Physicians, Appointed as Awakn’s Regional Director for the Nordics TORONTO, September ##, 2021 – Awakn Life Sciences Corp. (“Awakn”…

TORONTO, CANADA, 15 SEPTEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better…

TORONTO, CANADA, 02 SEPTEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic medicines to treat Addiction, announces that…

Recruitment Has Commenced for the First-Of-Its-Kind, U.K. – based Study, Led by Renowned Ketamine Researcher Toronto, Ontario–(Newsfile Corp. – August 24, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…

Toronto, Ontario–(Newsfile Corp. – August 12, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better…

Toronto, Ontario–(Newsfile Corp. – August 9, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to…

The clinic will deliver psychedelic-assisted psychotherapy treatments for Addiction and other mental health conditions and is scheduled to open during the fourth quarter of 2021. Awakn Clinics London will join…

Toronto, Ontario–(Newsfile Corp. – July 26, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to…

TORONTO, CANADA, 22 JULY 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to…

Program to focus on developing and delivering new treatments for substance and behavioral addictions. TORONTO, CANADA, 14 JULY 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company…

Awkan’s Chief Research Officer Prof David Nutt will chair both advisory boards with Prof Stephen Husbands, Prof Harriet De Wit, and Prof Kevin Fone joining the preclinical advisory board. TORONTO,…

Broadening of intellectual property portfolio for these two NCEs clearly defines development pathway for the next generation of psychedelic medicines to treat addiction TORONTO, CANADA, 28 June 2021 – Awakn…

PROF. NUTT WILL DRIVE PROGRESSION OF A PIPELINE OF NEW PSYCHEDELIC MEDICINES, HELPING TO DEFINE A CLEAR DEVELOPMENT PATHWAY TO TREAT ADDICTION THROUGH PSYCHEDELIC MEDICINES TORONTO, CANADA, 24 June 2021…

Vancouver, B.C., June 17, 2021 – Further to its press release date May 17, 2021, Awakn Life Sciences Corp. (formerly 1169082 B.C. Ltd.) (the “Company”) is pleased to announce that…

TORONTO, Ontario, June 10, 2021 – Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony…

Vancouver, B.C., June 8, 2021 – 1169082 B.C. Ltd. (the “Company”) and Awakn Life Sciences Inc. (“Awakn”), are pleased to announce the closing of the previously announced brokered private placement…

Vancouver, British Columbia–(Newsfile Corp. – May 17, 2021) – 1169082 B.C. Ltd. (the “Company”) is pleased to announce that it has entered into a definitive binding amalgamation agreement dated May 13, 2021…

Defining clear development pathway for next generation of psychedelic medicines to treat addiction Awakn announces today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline…

Awakn announces the appointment of Stephen Page and Professor John Papastergiou as independent non-executive directors to the company’s Board of Directors. Adding significant pharmaceutical and healthcare sector experience and independent…

First project to use advanced analytics to explore identity shifts in alcohol addiction Awakn launches ‘Awakn Digital’, a new unit focused on using advanced analytics to improve the effectiveness of…

Prof. Nutt appointed Head of Research to Lead Awakn’s Next-Gen Psychedelic Molecule Development Awakn Life Sciences announces the acquisition of significant proprietary research data on next generation candidate MDMA and…